Literature DB >> 463822

Toxicity of amphotericin b in children with cancer.

R Wilson, S Feldman.   

Abstract

The pattern of amphotericin B toxicity was assessed retrospectively in a group of 20 children with cancer who had received one or more courses of the drug for treatment of systemic fungal infection. Azotemia was the most frequent complication, developing during 23 of 24 treatment courses. Other major toxic effects, in decreasing order of frequency, were anemia, hypokalemia, thrombocytopenia, and neutropenia. Infusion side effects, including drug-related fever, chills, and nausea, were also frequently seen. Seventeen of 20 patients were treated for disseminated histoplasmosis. Nineteen of 20 patients had acute leukemia. Although interaction with other agents could not be excluded, amphotericin B appeared to be the major causative agent for the toxic reactions noted. In no patient, however, was administration of amphotericin B stopped because of drug toxicity.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 463822     DOI: 10.1001/archpedi.1979.02130070067014

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  3 in total

Review 1.  Clinical pharmacokinetics of systemic antifungal drugs.

Authors:  T K Daneshmend; D W Warnock
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

2.  Amphotericin B in children with malignant disease: a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion.

Authors:  C E Nath; P J Shaw; R Gunning; A J McLachlan; J W Earl
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

3.  Amphotericin B in Pediatrics: Analysis by Age Stratification Suggests a Greater Chance of Adverse Events from 13 Months of Age Onwards.

Authors:  Francelise Bridi Cavassin; João Luiz Baú-Carneiro; Fabio de Araújo Motta; Ana Paula Matzenbacher Ville; Leticia Staszczak; Flávio de Queiroz-Telles
Journal:  Paediatr Drugs       Date:  2022-07-18       Impact factor: 3.930

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.